Daiichi Sankyo Company, Limited (DSNKY) Stock Price & Analysis
Daiichi Sankyo Company, Limited (DSNKY) — price $16.95 (-0.94%), as of the Nov 20, 2026 trading session; market cap $30.9B.
Educational signal · not a buy or sell recommendation · How to read this
Daiichi Sankyo Company, Limited · DSNKY · Healthcare · Drug Manufacturers - General
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal…
Price as of Nov 20, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.95 | |
| Change on the day | -0.94% | |
| 52-week range | $14.98–$24.77 | |
| Market capitalisation | $30.9B | — |
| Price / earnings (trailing) | 18.00 | |
| Shares traded on the day | 9.6K | |
| Beta (volatility vs the S&P 500) | 0.14 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Daiichi Sankyo Company (DSNKY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Daiichi Sankyo Company (DSNKY), and what does it report?
Short answer
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal… Healthcare / Drug Manufacturers General Headquarters: Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP. It employs 20,171 people and is led by Hiroyuki Okuzawa. The market values it at $30.9B.
What are the financial strengths and risks for Daiichi Sankyo Company (DSNKY)?
Short answer
The distress and quality screens read Altman Z 2.95 · Piotroski F 6. Trailing ratios: ROE 17.6% · ROA 4.6% · current ratio 2.81.
How is Daiichi Sankyo Company scored?
Research dated 2026-09-12.
Daiichi Sankyo differs from oncology-focused biotechnology companies because its economics include a broad marketed portfolio, vaccines, consumer health products and pharmaceutical manufacturing activities. Enhertu gives oncology strategic importance, but the company is not a product-pure cancer developer.
Relative to diversified drug manufacturers, its notable feature is the combination of an antibody-drug conjugate franchise with development of a Guardant companion diagnostic for Enhertu in advanced metastatic lung cancer. That pairing links medicine commercialization with patient selection, while the consolidated accounts still blend newer oncology assets with mature therapies and consumer products.
The shares trade through an over-the-counter quotation, while the operating company is headquartered in Tokyo and distributes medicines globally. That listing route differs from the business itself and should not be read as evidence of a narrowly domestic operation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $45.10 Nov 20, 2026 | $14.9B | — Model unavailable | |
| $318.32 Nov 20, 2026 | $60.7B | — Model unavailable | |
| $143.12 Nov 20, 2026 | $47.5B | — Model unavailable | |
| $43.05 Nov 20, 2026 | $68.8B | — Model unavailable | |
| $23.77 Nov 20, 2026 | $72.2B | — Model unavailable | |
| $247.13 Nov 19, 2026 | $36.5B | — 5-pillar · not comparable | |
| $47.76 Nov 20, 2026 | $95.7B | — 5-pillar · not comparable | |
| $46.06 Nov 19, 2026 | $111B | — 5-pillar · not comparable | |
| $58.80 Nov 20, 2026 | $120B | — 5-pillar · not comparable | |
| $27.54 Nov 19, 2026 | $157B | — 5-pillar · not comparable | |
| $8.15 Nov 20, 2026 | $5.55B | — 5-pillar · not comparable | |
| $166.53 Nov 19, 2026 | $207B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DSNKY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DSNKY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Daiichi Sankyo Company (DSNKY)?
- Will Cancer Drug Delivery Partnership Change Daiichi Sankyo Stock Narrative
- iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
- Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
Daiichi Sankyo Company Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Does Enhertu make Daiichi Sankyo a pure oncology company?
Enhertu is an important antibody-drug conjugate, but Daiichi Sankyo also sells medicines across cardiovascular, metabolic, neurological, pain, bone and infectious diseases, as well as vaccines and consumer health products.
How does the Guardant companion diagnostic fit with Enhertu?
Daiichi Sankyo is collaborating with Guardant Health on a companion diagnostic specifically for Enhertu use in advanced metastatic lung cancer. The development connects treatment commercialization with identification of suitable patients.
What is the DSNKY stock price today?
The last price recorded for Daiichi Sankyo Company, Limited (DSNKY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 12 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com